• Odyssey Health is focused on developing life-saving medical products and pharmaceutical assets that offer a technological and clinical advantage
• The company is developing the CardioMap Heart Monitoring and Screening Device and the Save-a-Life choking rescue device 
• Its drug-device combination is intended to get PRV-002, Odyssey’s novel treatment for concussion, to the brain rapidly after concussion
• In an interview with RedChip Companies CEO Dave Gentry, Odyssey CEO Michael Redmond outlined the timelines under which the company is operating as it eyes the commercialization of its novel drug candidate

Medical company Odyssey Health (OTC: ODYY) is working to provide life-saving medical solutions that offer clinical advantages to unmet medical needs. The company boasts a repertoire of several products that include the CardioMap Heart Monitoring and Screening Device and the Save-a-Life choking rescue device, both of which are in development and are, therefore, not yet commercially available, as well as a novel breath-propelled nasal delivery device designed to deliver the company’s novel treatment for concussion, PRV-002.

Nasal Delivery Device

The nasal delivery device, which was the subject of a patent application filed last fall (https://ibn.fm/9c2KZ), is part of a drug-device combination that is being used in Odyssey’s ongoing Phase I clinical trial investigating how well PRV-002 is tolerated by healthy human subjects. “It’s a small device that essentially delivers a powdered drug through the upper chambers of the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.